Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the ...

A subgroup analysis of the phase 3 FOCUS study (NCT02678572) shows that the Melphalan/Hepatic Delivery System (HDS; HEPZATO ...

Delcath Systems announces publication of subgroup analyses of phase 3 FOCUS study of Melphalan/Hepatic Delivery System in patients with unresectable metastatic uveal melanoma Queensbury, New York ...

Kezar Life Sciences, Inc. (Nasdaq:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that the ...

Scientists have found that combining silybin with carvedilol works far better against liver fibrosis than either drug alone.

HER2CLIMB-05 trial evaluated Tukysa in combination with Herceptin and Perjeta for HER2-positive metastatic breast cancer, ...

The study reveals that nicotinic acid (vitamin B3) significantly protects the liver during ischemia-reperfusion injury by ...

The Hepzato Kit is the first FDA-approved liver-directed therapy for unresectable metastatic uveal melanoma, showing ...

The HER2CLIMB-05 study assessed the efficacy and safety of adding tucatinib to maintenance therapy with trastuzumab/pertuzumab in patients with HER2+ metastatic breast cancer.

MindRank, a clinical-stage artificial intelligence (AI)-empowered drug discovery company, today announced the initiation of "MOBILE," a pivotal Phase III clinical trial evaluating its lead candidate, ...

Going by his words, understanding the human brain is far more complex than comprehending the entire solar system. Veteran ...

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully integrated, commercial biotechnology company, announced today that Tonix management will present and host investor ...